Hepatitis C Virus Infection Pipeline Insight 2025: Next-Generation Direct-Acting Antivirals and Immune-Based Therapies Transform the Treatment Landscape | DelveInsight

DelveInsight's "Hepatitis C Virus Infection - Pipeline Insight, 2025" provides a comprehensive overview of the evolving therapeutic landscape for HCV, a global health burden affecting millions and a leading cause of liver cirrhosis and hepatocellular carcinoma. Despite the success of current direct-acting antivirals (DAAs), challenges remain in treatment-experienced patients, those with advanced liver disease, and in resource-limited settings, driving ongoing innovation.

The 2025 pipeline highlights the emergence of next-generation DAAs, pan-genotypic regimens, and host-targeted immunotherapies aiming to improve efficacy, shorten treatment durations, and enhance safety profiles. Agents such as Gilead's next-gen pan-genotypic protease inhibitors and Merck's combination regimens targeting NS5A/NS5B are demonstrating high sustained virologic response (SVR) rates even in patients with prior DAA failure or cirrhosis.

In parallel, immune-based therapies and therapeutic vaccines are advancing through early-phase trials, targeting viral reservoirs and aiming to reduce relapse risk and long-term liver complications. RNA interference (RNAi) therapies and novel host-directed antiviral approaches are also being explored to enhance viral clearance and reduce resistance emergence.

From a regulatory and market perspective, breakthrough therapy designations, orphan drug statuses for rare genotypes, and real-world data integration are accelerating development timelines. Clinical trials increasingly incorporate patient-reported outcomes, liver function biomarkers, and time-to-SVR metrics to better capture both short- and long-term benefits.

With a robust pipeline of direct-acting, immune-modulating, and host-targeted therapies, HCV management is moving toward personalized, simplified regimens that could further reduce global disease burden and offer durable viral eradication across diverse patient populations.

Interested in learning more about the current treatment landscape and the key drivers shaping the Hepatitis C Virus Infection pipeline? Click here: https://www.delveinsight.com/report-store/hepatitis-c-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Hepatitis C Virus Infection Pipeline Report
• DelveInsight's Hepatitis C Virus Infection pipeline analysis depicts a strong space with 20+ active players working to develop 20+ pipeline drugs for Hepatitis C Virus Infection treatment.
• The leading Hepatitis C Virus Infection companies include Sunshine Lake Pharma Co., Ltd., GeneCure Biotechnologies, Biotron, Cocrystal Pharma, Genecure Biotechnologies Preclinical, iQur, Atea Pharmaceutical, Dongguan HEC TaiGen Biopharmaceuticals, Nanjing Sanhome Pharmaceutical, and others are evaluating their lead assets to improve the Hepatitis C Virus Infection treatment landscape.
• Key Hepatitis C Virus Infection pipeline therapies in various stages of development include HEC74647PA+HEC110114, HCVax, BIT 225, CC-31244, Prophylactic HCV vaccine, iQur Research programme, Bemnifosbuvir + Ruzasvir, TG-2349, SH229, and others.
• In June 2025, AbbVie announced that the FDA approved a label expansion for MAVYRET® (glecaprevir/pibrentasvir) to treat adults and children aged three and older with acute or chronic hepatitis C virus (HCV) infection, with or without compensated cirrhosis. MAVYRET is now the first and only direct-acting antiviral approved for an eight-week treatment of acute HCV with a 96% cure rate.
• In March 2025, following a successful End-of-Phase 2 meeting with the FDA in January 2025, Atea is launching its global Phase 3 program for hepatitis C, with patient enrollment set to begin in April 2025. In December 2024, Atea announced that its Phase 2 study of bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV) met its primary endpoints.

Request a sample and discover the recent breakthroughs happening in the Hepatitis C Virus Infection pipeline landscape at https://www.delveinsight.com/report-store/hepatitis-c-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Hepatitis C Virus Infection Overview
Hepatitis C is a liver infection caused by the hepatitis C virus, primarily spread through contact with infected blood. While some people clear the virus on their own, most develop chronic infection, which can lead to liver inflammation, fibrosis, cirrhosis, or liver cancer if untreated. Often called a "silent" infection, HCV may go undetected for years due to mild or no symptoms. Modern antiviral treatments can cure over 95% of cases, but access and early diagnosis remain challenges. Prevention focuses on safe injection practices, blood screening, and public health awareness.

Find out more about Hepatitis C Virus Infection medication at https://www.delveinsight.com/report-store/hepatitis-c-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Hepatitis C Virus Infection Treatment Analysis: Drug Profile
TG-2349: Dongguan HEC TaiGen Biopharmaceuticals
TG-2349 (Furaprevir) is a protease inhibitor developed as a direct-acting antiviral for the oral treatment of chronic Hepatitis C Virus (HCV) infection. It has completed Phase III clinical trials in combination with DAG181 and Ribavirin over a 12-week regimen in patients with HCV Genotype I.

CC-31244: Cocrystal Pharma
CC-31244 is a non-nucleoside inhibitor (NNI) targeting the HCV NS5B polymerase, with pan-genotypic activity. Positioned as a potential best-in-class therapy, it may enable ultra-short, all-oral treatment regimens for HCV. The drug is currently in Phase IIa clinical development.

Learn more about the novel and emerging Hepatitis C Virus Infection pipeline therapies at https://www.delveinsight.com/report-store/hepatitis-c-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Hepatitis C Virus Infection Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

By Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide

Scope of the Hepatitis C Virus Infection Pipeline Report
• Coverage: Global
• Key Hepatitis C Virus Infection Companies: Sunshine Lake Pharma Co., Ltd., GeneCure Biotechnologies, Biotron, Cocrystal Pharma, Genecure Biotechnologies Preclinical, iQur, Atea Pharmaceutical, Dongguan HEC TaiGen Biopharmaceuticals, Nanjing Sanhome Pharmaceutical, and others.
• Key Hepatitis C Virus Infection Pipeline Therapies: HEC74647PA+HEC110114, HCVax, BIT 225, CC-31244, Prophylactic HCV vaccine, iQur Research programme, Bemnifosbuvir + Ruzasvir, TG-2349, SH229, and others.

To dive deep into rich insights for drugs used for Hepatitis C Virus Infection treatment, visit: https://www.delveinsight.com/report-store/hepatitis-c-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Hepatitis C Virus Infection Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Hepatitis C Virus Infection Pipeline Therapeutics
6. Hepatitis C Virus Infection Pipeline: Late-Stage Products (Phase III)
7. Hepatitis C Virus Infection Pipeline: Mid-Stage Products (Phase II)
8. Hepatitis C Virus Infection Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.